Grünenthal Pharma produces for Biofrontera

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Leverkusen, Germany - Biofrontera AG (DSE: B8F) in Leverkusen and
Grünenthal Pharma AG in Switzerland will in the future cooperate on
product manufacturing. The companies Biofrontera Pharma GmbH,
Leverkusen, and Grünenthal Pharma AG, Mitlödi/Switzerland, have
signed an agreement for the production of Biofrontera's products
BF-200 ALA and Reliéva. BF-200 ALA is a dermatological drug for the
treatment of actinic keratosis, Reliéva a medicinal skin care product
line for nourishing skin with dandruff, dermatitis, or itching.

The Grünenthal Pharma AG obtains rights for the European production
of both products for 7 years following market introduction. In return
Grünenthal covers all costs for the development of the entire
production process, the manufacturing of the stability batches and
the analytical tests.
Pharmaceutical products such as BF-200 ALA and Reliéva must be
produced under GMP (Good Manufacturing Practice) conditions,
requiring detailed documentation of the manufacturing processes. Such
products can only be launched if they have excellent and fully
documented quality and purity. Moreover, the manufacturer has to
guarantee the stability and reproducibility of the entire production
process.

Reliéva will be introduced into the market within only few months.
BF-200 ALA is currently tested in the final pivotal phase III
clinical trial. In a first, completed phase III trial, BF-200 ALA has
already demonstrated excellent efficacy. Based on the high innovation
potential of BF-200 ALA the European authority EMEA has agreed to a
centralized registration procedure.

"Biofrontera could find an excellent partner in Grünenthal",
commented the CEO of Biofrontera AG, Prof. Dr. Hermann Lübbert the
agreement.
The strong interest of Grünenthal Pharma AG underlines the very
positive assessment of the market potentials of Reliéva and BF-200
ALA, stated Lübbert. He is looking forward to expand potential
business relationships with Grünenthal in the near future.

About Biofrontera AG
Biofrontera AG is specialized in the development of pharmaceutical
products in the area of dermatology. The company is characterized by
a broad, relatively close to the market product portfolio.
Biofrontera is listed in the regulated market of the Düsseldorf stock
exchange under the symbol B8F and the ISIN number DE0006046113.
www.biofrontera.com

About Grünenthal
Grünenthal is an expert in pain therapy and gynaecology and a pioneer
in intelligent, user-friendly drug delivery technologies. The company
discovers, develops, produces and markets high therapeutic value
pharmaceuticals that contribute to patients' ability to control their
own lives. Grünenthal is an independent, family-owned German company
with companies in 32 countries all over the world. Founded in 1946,
the company employs 1,900 people in Germany and 5,300 worldwide. In
2007, Grünenthal achieved revenues of 846 million Euros. More
information: www.grunenthal.com

This press release contains forward-looking statements based on the
currently held beliefs and assumptions of the management of
Biofrontera AG, which are expressed in good faith and, in their
opinion, reasonable. Forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the
assumptions expressed or implied in this press release to be faulty.
Given these risks, uncertainties and other factors, recipients of
this document are cautioned not to place undue reliance on the
forward-looking statements. Biofrontera AG disclaims any obligation
to update these forward-looking statements to reflect future events
or developments.

For further information please contact:

Anke zur Mühlen
Corporate Communication

+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen@biofrontera.com

Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany

--- End of Message ---

Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;
ISIN: DE0006046113;
Listed: Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse
München,
Freiverkehr in Börse Stuttgart, Open Market in Frankfurter
Wertpapierbörse,
Regulierter Markt in Börse Düsseldorf;
Copyright © Hugin AS 2009. All rights reserved.